TV News LIES

Thursday, Jul 30th

Last update03:51:21 AM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.

More...


Most Recent Related Stories...


'Jaw-dropping': Medicare deaths, hospitalizations AND costs reduced

Medicare reductions in deathsThe U.S. health care system has scored a medical hat trick, reducing deaths, hospitalizations and costs,...

More Than 100 Doctors Tell Big Pharma To Stop Making Cancer Drugs So Expensive

Cancer profits by Big PharmaThe pressure is mounting on pharmaceutical companies to lower their prices for lifesaving drugs, as a...

FDA reviews nutrition label change to highlight added sugar

added sugarThe Food and Drug Administration is reviewing a controversial change to nutrition labels to add amounts...

CT scans cause measurable damage to cells, say researchers

CT ScansResearchers have found links between computed tomography (CT) scanning and cell damage in the body, linking...
 
America's # 1 Enemy
Tee Shirt
& Help Support TvNewsLIES.org!
TVNL Tee Shirt
 
TVNL TOTE BAG
Conserve our Planet
& Help Support TvNewsLIES.org!
 
Get your 9/11 & Media
Deception Dollars
& Help Support TvNewsLIES.org!
 
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!